A large number of experimental studies and few clinicalobservations have suggested that PPAR-γligands may be successfully exploited to treat a wide range of neurologicaldiseases, ranging from neurodegenerative diseases, to traumatic injuries,stroke, and demyelinating diseases, as recently reviewed by Heneka et al. [5].In Alzheimer's disease (AD) transgenic mouse models, the TZD rosiglitazone attenuatedlearning and memory deficits [6], in line with its ability to promote cognitivepreservation in patients with early AD [7, 8]. Here, PPARA is linked to Alzheimer disease.